Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia

NCT05240976 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: NMDAE plus AIFA
DRUG: NMDAE plus Placebo Cap

Sponsor

China Medical University Hospital

Collaborators

[object Object]